Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22799528 | 1.00 | GAA (0.41) | GAAALDH1A1TSHRKMT2ABCHE | |
| SCHEMBL24674052 | 1.00 | GAA (0.41) | GAAALDH1A1TSHRKMT2ABCHE | |
| SCHEMBL22797591 | 1.00 | GAA (0.41) | GAAALDH1A1TSHRKMT2ABCHE | |
| SCHEMBL24673918 | 1.00 | GAA (0.41) | GAAALDH1A1TSHRKMT2ABCHE | |
| SCHEMBL24673107 | 1.00 | GAA (0.41) | GAAALDH1A1TSHRKMT2ABCHE | |
| SCHEMBL24674047 | 1.00 | GAA (0.41) | GAAALDH1A1TSHRKMT2ABCHE | |
| SCHEMBL24673074 | 1.00 | GAA (0.41) | GAAALDH1A1TSHRKMT2ABCHE | |
| SCHEMBL24674049 | 1.00 | GAA (0.41) | GAAALDH1A1TSHRKMT2ABCHE | |
| SCHEMBL22797590 | 1.00 | GAA (0.41) | GAAALDH1A1TSHRKMT2ABCHE | |
| SCHEMBL22797529 | 0.89 | GAA (0.40) | GAAALDH1A1TSHRKMT2ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220275018-A1 | NOVEL SPIROBICYCLIC INTERMEDIATES | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275018-A1 | NOVEL SPIROBICYCLIC INTERMEDIATES | NME2, SLC28A1, SLC28A2 | GAA 3330/4885ALDH1A1 248/4885TSHR 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.